Skip to main content
Erschienen in: Urolithiasis 1/2015

01.02.2015 | Original Paper

Folium pyrrosiae ingestion has no effect on the thermodynamic or kinetic urinary risk factors for calcium oxalate urolithiasis in healthy subjects: a poor prognosis for alternative treatment in this type of stone former

verfasst von: Allen L. Rodgers, Dawn Webber, Ronica Ramsout, Mayur Danny I. Gohel

Erschienen in: Urolithiasis | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Kidney stone disease occurs throughout the world. Conservative treatments involving herbal preparations have been used in traditional Chinese medicine. In vitro studies have suggested that Folium pyrrosiae (FP) has therapeutic potential in this context. The present study was undertaken to investigate the effects of ingested FP on urinary thermodynamic and kinetic risk factors for calcium oxalate (CaOx) stone formation in subjects from two different population groups. Healthy white (n = 9) and black (n = 9) males ingested 1.5 g FP each day for 7 days. 24 h urines (baseline and day 7) and blood samples (baseline and day 3) were collected. Urines were analyzed for lithogenic risk factors and were subjected to CaOx crystallization experiments in which the metastable limit (MSL), particle size-volume distribution and crystal deposition kinetics were determined. Urine composition values were used to calculate the relative supersaturation (RS) of CaOx and other urinary salts. Blood samples were analyzed for liver enzymes to monitor the safety of the protocol. Food diaries were recorded on days 0 and 7. Data were analyzed statistically using standard software. Nutrient intakes and the concentration of liver enzymes did not change during the study. No side effects were reported. There were no statistically significant differences in any of the thermodynamic (RS, MSL) or kinetic (particle volume-size distribution, crystal deposition rate) risk factors for CaOx stone formation in either of the groups following ingestion of FP relative to baseline values. FP does not have potential as a therapeutic agent in the management of CaOx kidney stone disease.
Literatur
1.
Zurück zum Zitat Sutherland JW, Parks JH, Coe FL (1985) Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 11:267–269PubMed Sutherland JW, Parks JH, Coe FL (1985) Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 11:267–269PubMed
2.
Zurück zum Zitat Milliner DS (1995) Epidemiology of calcium oxalate urolithiasis in man. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press, Boca Raton, pp 169–188 Milliner DS (1995) Epidemiology of calcium oxalate urolithiasis in man. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press, Boca Raton, pp 169–188
3.
Zurück zum Zitat Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116(3):159–171CrossRef Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116(3):159–171CrossRef
4.
Zurück zum Zitat Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K (1995) The inhibitory effect of Kampou extracts and in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol 2:81–86PubMedCrossRef Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K (1995) The inhibitory effect of Kampou extracts and in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol 2:81–86PubMedCrossRef
5.
Zurück zum Zitat Glover M, Zuber AM, O’Shaughnessy KM (2011) Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 29(1):68–76PubMedCrossRef Glover M, Zuber AM, O’Shaughnessy KM (2011) Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 29(1):68–76PubMedCrossRef
6.
Zurück zum Zitat Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006023.pub2 PubMed Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. doi:10.​1002/​14651858.​CD006023.​pub2 PubMed
7.
Zurück zum Zitat Atmani F (2003) Medical management of urolithiasis, what opportunity for phytotherapy? Front Biosci 8:507–514CrossRef Atmani F (2003) Medical management of urolithiasis, what opportunity for phytotherapy? Front Biosci 8:507–514CrossRef
8.
Zurück zum Zitat Gürocak S, Küpeli B (2006) Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review. J Urol 176:405–455CrossRef Gürocak S, Küpeli B (2006) Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review. J Urol 176:405–455CrossRef
9.
Zurück zum Zitat Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med 75:1092–1103 Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? Planta Med 75:1092–1103
10.
Zurück zum Zitat Yadav RD, Alok S, Jain SK, Verma A, Mahor A, Bharti JP, Jaiswal M (2011) Herbal plants used in the treatment of urolithiasis: a review. IJPSR 2(6):1412–1420 Yadav RD, Alok S, Jain SK, Verma A, Mahor A, Bharti JP, Jaiswal M (2011) Herbal plants used in the treatment of urolithiasis: a review. IJPSR 2(6):1412–1420
11.
Zurück zum Zitat Leung P, Biji S, Yeung C (2011) Chinese medicine and the surgeon. Chin J Integr Med 17(7):548–555PubMedCrossRef Leung P, Biji S, Yeung C (2011) Chinese medicine and the surgeon. Chin J Integr Med 17(7):548–555PubMedCrossRef
12.
Zurück zum Zitat Hoffman H (1983) The new holistic herbs. In: Hoffman H (ed) The urinary system. Element Books Limited, London, pp 108–111 Hoffman H (1983) The new holistic herbs. In: Hoffman H (ed) The urinary system. Element Books Limited, London, pp 108–111
13.
Zurück zum Zitat He X (2012) Traditional Chinese medicine for treatment of urinary stones. In: Talati JJ (ed) Urolithiasis. Springer-Verlag, London, pp 539–541CrossRef He X (2012) Traditional Chinese medicine for treatment of urinary stones. In: Talati JJ (ed) Urolithiasis. Springer-Verlag, London, pp 539–541CrossRef
14.
Zurück zum Zitat Chen JK, Chen TT (2004) Chinese medical herbology and pharmacology, 2nd edn. The Art of Medicine Press Inc, California Chen JK, Chen TT (2004) Chinese medical herbology and pharmacology, 2nd edn. The Art of Medicine Press Inc, California
15.
Zurück zum Zitat Gohel MDI, Wong SP (2006) Chinese herbal medicines and their efficacy in treating renal stones. Urol Res 34:365–372PubMedCrossRef Gohel MDI, Wong SP (2006) Chinese herbal medicines and their efficacy in treating renal stones. Urol Res 34:365–372PubMedCrossRef
16.
Zurück zum Zitat Rodgers AL, Webber D, Ramsout R, Gohel MDI (2014) Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy. Urolithiasis. doi:10.1007/s00240-014-0654-3 (in press) Rodgers AL, Webber D, Ramsout R, Gohel MDI (2014) Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy. Urolithiasis. doi:10.​1007/​s00240-014-0654-3 (in press)
18.
Zurück zum Zitat Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef Khan SR (2006) Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res 34:86–91PubMedCrossRef
19.
Zurück zum Zitat Grases F, Costa-Bauzá A, Königsberger E, Königsberger L-C (2000) Kinetic versus thermodynamic factors in renal lithiasis. Int Urol Nephrol 32:19–27PubMedCrossRef Grases F, Costa-Bauzá A, Königsberger E, Königsberger L-C (2000) Kinetic versus thermodynamic factors in renal lithiasis. Int Urol Nephrol 32:19–27PubMedCrossRef
20.
Zurück zum Zitat Rodgers AL, Lewandowski S (2002) Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups. J Urol 168:931–936PubMedCrossRef Rodgers AL, Lewandowski S (2002) Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups. J Urol 168:931–936PubMedCrossRef
21.
Zurück zum Zitat Theka T, Rodgers A, Lewandowski S, Webber D, Allie-Hamdulay S (2012) Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms. Urol Res 40(2):113–120PubMedCrossRef Theka T, Rodgers A, Lewandowski S, Webber D, Allie-Hamdulay S (2012) Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms. Urol Res 40(2):113–120PubMedCrossRef
22.
Zurück zum Zitat Li J, Tong YY (1992) Determination of the active constituents in shi-wei (Folium pyrrosiae) by high performance liquid chromatography. Yao XueXueBao 27(2):153–156 Li J, Tong YY (1992) Determination of the active constituents in shi-wei (Folium pyrrosiae) by high performance liquid chromatography. Yao XueXueBao 27(2):153–156
23.
Zurück zum Zitat Allie-Hamdulay S, Rodgers AL (2005) Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 33:116–124PubMedCrossRef Allie-Hamdulay S, Rodgers AL (2005) Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial. Urol Res 33:116–124PubMedCrossRef
24.
Zurück zum Zitat Lee M (2009) Basic Skills in interpreting laboratory data, 4th edn. American Society of Health-System Pharmacists, Bethesda Lee M (2009) Basic Skills in interpreting laboratory data, 4th edn. American Society of Health-System Pharmacists, Bethesda
25.
Zurück zum Zitat Tiselius HG (1982) An improvement method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122(3):409–418PubMedCrossRef Tiselius HG (1982) An improvement method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122(3):409–418PubMedCrossRef
26.
Zurück zum Zitat Werness PG, Brown CM, Smith LH, Finlayson B (1985) EQUIL 2: a basic computer program for the calculation of urinary supersaturation. J Urol 134:1242–1244PubMed Werness PG, Brown CM, Smith LH, Finlayson B (1985) EQUIL 2: a basic computer program for the calculation of urinary supersaturation. J Urol 134:1242–1244PubMed
27.
Zurück zum Zitat Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 13(6):285–289PubMedCrossRef Ryall RL, Hibberd CM, Marshall VR (1985) A method for studying inhibitory activity in whole urine. Urol Res 13(6):285–289PubMedCrossRef
28.
Zurück zum Zitat Ryall RL, Grover PK, Stapelton AM, Barrell DK, Tang Y, Moritz RL, Simpson RJ (1995) The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89:533–541PubMed Ryall RL, Grover PK, Stapelton AM, Barrell DK, Tang Y, Moritz RL, Simpson RJ (1995) The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89:533–541PubMed
29.
Zurück zum Zitat Ryall RL (2011) The possible role of inhibitors, promoters and macromolecules in the formation of calcium kidney stones. In: Rao NP, Preminger GM, Kavanagh JP (eds) Urinary tract stone disease. Springer, London, pp 31–60 Ryall RL (2011) The possible role of inhibitors, promoters and macromolecules in the formation of calcium kidney stones. In: Rao NP, Preminger GM, Kavanagh JP (eds) Urinary tract stone disease. Springer, London, pp 31–60
30.
Zurück zum Zitat Hess B, Jordi S, Zipperle L, Ettinger E, Giovanoli R (2000) Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 15(3):366–374PubMedCrossRef Hess B, Jordi S, Zipperle L, Ettinger E, Giovanoli R (2000) Citrate determines calcium oxalate crystallization kinetics and crystal morphology-studies in the presence of Tamm-Horsfall protein of a healthy subject and a severely recurrent calcium stone former. Nephrol Dial Transplant 15(3):366–374PubMedCrossRef
31.
Zurück zum Zitat Kok DJ, Papapoulos SE, Blomen LJ, Bijvoet OL (1988) Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34(3):346–350PubMedCrossRef Kok DJ, Papapoulos SE, Blomen LJ, Bijvoet OL (1988) Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34(3):346–350PubMedCrossRef
32.
Zurück zum Zitat Kok DJ, Papapoulos SE, Bijvoet OL (1990) Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37(1):51–56PubMedCrossRef Kok DJ, Papapoulos SE, Bijvoet OL (1990) Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37(1):51–56PubMedCrossRef
33.
Zurück zum Zitat Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N (2004) Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 32(5):362–366PubMedCrossRef Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N (2004) Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 32(5):362–366PubMedCrossRef
34.
Zurück zum Zitat Micali S, Sighinolfi MC, Celia A, De Stefani S, Grande M, Cicero AF, Bianchi G (2006) Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 176(3):1020–1022PubMedCrossRef Micali S, Sighinolfi MC, Celia A, De Stefani S, Grande M, Cicero AF, Bianchi G (2006) Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 176(3):1020–1022PubMedCrossRef
35.
Zurück zum Zitat ShekarKumaran MG, Patki PS (2011) Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: a double blind, placebo-controlled study. Eur J Integr Med 3:23–28CrossRef ShekarKumaran MG, Patki PS (2011) Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: a double blind, placebo-controlled study. Eur J Integr Med 3:23–28CrossRef
36.
Zurück zum Zitat Permgamone A, Sriboonlue P, Disatapornjaroen W, Maskasem S, Sinsupan N, Apinives C (2001) A long-term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment. Southeast Asian J Trop Med Public Health 32(3):654–660 Permgamone A, Sriboonlue P, Disatapornjaroen W, Maskasem S, Sinsupan N, Apinives C (2001) A long-term study on the efficacy of a herbal plant, Orthosiphon grandiflorus, and sodium potassium citrate in renal calculi treatment. Southeast Asian J Trop Med Public Health 32(3):654–660
37.
Zurück zum Zitat Calixto JB, Santos AR, Cechinel FV, Yunes RA (1998) A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 18(4):225–258PubMedCrossRef Calixto JB, Santos AR, Cechinel FV, Yunes RA (1998) A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 18(4):225–258PubMedCrossRef
38.
Zurück zum Zitat Kieley S, Dwivedi R, Monga M (2008) Ayurvedic medicine and renal calculi. J Endourol 22(8):1613–1616PubMedCrossRef Kieley S, Dwivedi R, Monga M (2008) Ayurvedic medicine and renal calculi. J Endourol 22(8):1613–1616PubMedCrossRef
39.
Zurück zum Zitat Schwartz BF, Schenkman N, Nguyen R, Stoller ML (2000) Gahat: a Napalese cure for urolithiasis? Urology 56:912–914PubMedCrossRef Schwartz BF, Schenkman N, Nguyen R, Stoller ML (2000) Gahat: a Napalese cure for urolithiasis? Urology 56:912–914PubMedCrossRef
Metadaten
Titel
Folium pyrrosiae ingestion has no effect on the thermodynamic or kinetic urinary risk factors for calcium oxalate urolithiasis in healthy subjects: a poor prognosis for alternative treatment in this type of stone former
verfasst von
Allen L. Rodgers
Dawn Webber
Ronica Ramsout
Mayur Danny I. Gohel
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 1/2015
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-014-0722-8

Weitere Artikel der Ausgabe 1/2015

Urolithiasis 1/2015 Zur Ausgabe

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.